Generation of predictive pharmacophore models for CCR5 antagonists: Study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 21, 2003, Pages 4501-4515

  Debnath, Asim Kumar ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; BUPRENORPHINE; CHEMOKINE RECEPTOR CCR5; CLOZAPINE; E 913; MORPHINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; ROPINIROLE; SCH 350634; SUMATRIPTAN; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; NONHUMAN; PHARMACOPHORE; VALIDATION PROCESS; VIRUS INHIBITION;

ALGORITHMS; ANTI-HIV AGENTS; CATALYSIS; HIV-1; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PIPERAZINES; PIPERIDINES; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141889021     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030265z     Document Type: Article

References (87)

1. AIDS Epidemic Update-2002. UNAIDS/WHO: Geneva, 2003.
2. Weitzel, T.; Plettenberg, A.; Albrecht, D.; Lorenzen, T.; Stoehr, A. Severe anemia as a newly recognized side-effect caused by lamivudine. AIDS 1999, 13, 2309-2311.
3. Fortuny, C.; Vicente, M. A.; Medina, M. M.; Gonzalez-Ensenat, A. Rash as side-effect of nelfinavir in children. AIDS 2000, 14, 335-336.
4. Das, S. J.; Olsen, I. Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. Cytokine 2000, 12, 1566-1569.
5. Savini, C. J.; James, C. W.; Miller, J. L.; Wilson, S. A.; Cohen, D. M.; Perlada, D. E. Evidence of hypertriglyceridemia in managing HIV patients on efavirenz. J. Assoc. Nurses AIDS Care 2001, 12, 95-97.
6. Foli, A.; Benvenuto, F.; Piccinini, G.; Bareggi, A.; Cossarizza, A.; Lisziewicz, J.; Lori, F. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001, 15, 1687-1694.
7. Ahlsen, G.; Hulten, J.; Shuman, C. F.; Poliakov, A.; Lindgren, M. T.; Alterman, M.; Samuelsson, B.; Hallberg, A.; Danielson, U. H. Resistance profiles of cyclic and linear inhibitors of HIV-1 protease. Antiviral Chem. Chemother. 2002, 13, 27-37.
8. Blaise, P.; Clevenbergh, P.; Vaira, D.; Moutschen, M.; Dellamonica, P. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin. Belg. 2002, 57, 191-201.
9. Kuritzkes, D. R. Resistance to protease inhibitors. J. HIV Ther. 2002, 7, 87-91.
10. Fusion inhibitors: T-20 and T-1249. Treatmentupdate 2001, 12, 2-3.
11. James, J. S. T-20: most expensive AIDS drug ever at $25,000 per year? AIDS Treat. News 2003, 6-7.
12. Hanna, L. T-20: first of a new class of anti-HIV drugs. BETA 1999, 12, 7-8.
13. Sharp, M.; Camp, R. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank? GMHC Treat. Issues 2003, 17, 7-8.
14. Cooley, L. A.; Lewin, S. R. HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol. 2003, 26, 121-132.
15. Ketas, T. J.; Klasse, P. J.; Spenlehauer, C.; Nesin, M.; Frank, I.; Pope, M.; Strizki, J. M.; Reyes, G. R.; Baroudy, B. M.; Moore, J. P. Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types. AIDS Res. Hum. Retroviruses 2003, 19, 177-186.
16. Trkola, A.; Kuhmann, S. E.; Strizki, J. M.; Maxwell, E.; Ketas, T.; Morgan, T.; Pugach, P.; Xu, S.; Wojcik, L.; Tagat, J.; Palani, A.; Shapiro, S.; Clader, J. W.; McCombie, S.; Reyes, G. R.; Baroudy, B. M.; Moore, J. P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 395-400.
17. Brelot, A.; Alizon, M. HIV-1 entry and how to block it. AIDS 2001, 15 (Suppl. 5), S3-S11.
18. Moore, J. P.; Trkola, A.; Dragic, T. Co-receptors for HIV-1 entry. Curr Opin. Immunol. 1997, 9, 551-562.
19. Sodroski, J. G. HIV-1 entry inhibitors in the side pocket. Cell 1999, 99, 243-246.
20. Stein, B. S.; Engleman, E. G. Mechanism of HIV-1 entry into CD4+ T cells. Adv. Exp. Med. Biol. 1991, 300, 71-86.
21. Cocchi, F.; DeVico, A. L.; Garzino-Demo, A.; Arya, S. K.; Gallo, R. C.; Lusso, P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270, 1811-1815.
22. Liu, R.; Paxton, W. A.; Choe, S.; Ceradini, D.; Martin, S. R.; Horuk, R. ; MacDonald, M. E.; Stuhlmann, H.; Koup, R. A.; Landau, N. R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86, 367-377.
23. Marmor, M.; Sheppard, H. W.; Donnell, D.; Bozeman, S.; Celum, C.; Buchbinder, S.; Koblin, B.; Seage, G. R., III. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J. Acquired Immune Defic. Syndr. 2001, 27, 472-481.
24. Samson, M.; Libert, F.; Doranz, B. J.; Rucker, J.; Liesnard, C.; Farber, C. M.; Saragosti, S.; Lapoumeroulie, C.; Cognaux, J.; Forceille, C.; Muyldermans, G.; Verhofstede, C.; Burtonboy, G.; Georges, M.; Imai, T.; Rana, S.; Yi, Y.; Smyth, R. J.; Collman, R. G.; Doms, R. W.; Vassart, G.; Parmentier, M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382, 722-725.
25. Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C. ; Kenakin, T. Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors. Bioorg. Med. Chem. 2003, 11, 2663-2667.
26. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K.; Fujino, M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5698-5703.
27. Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Cox, K.; Strizki, J.; Endres, M.; Baroudy, B. M. Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl) carbonyl]-4′-methyl-1,4′-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem. 2001, 44, 3339-3342.
28. Palani, A.; Shapiro, S.; Josien, H.; Bara, T.; Clader, J. W.; Greenlee, W. J.; Cox, K.; Strizki, J. M.; Baroudy, B. M. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J. Med. Chem. 2002, 45, 3143-3160.
29. Strizki, J. M.; Xu, S.; Wagner, N. E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Tagat, J. R.; McCombie, S.; Cox, K.; Fawzi, A. B.; Chou, C. C.; Pugliese-Sivo, C.; Davies, L.; Moreno, M. E.; Ho, D. D.; Trkola, A.; Stoddart, C. A.; Moore, J. P.; Reyes, G. R.; Baroudy, B. M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12718-12723.
30. Tsamis, F.; Gavrilov, S.; Kajumo, F.; Seibert, C.; Kuhmann, S.; Ketas, T.; Trkola, A.; Palani, A.; Clader, J. W.; Tagat, J. R.; McCombie, S.; Baroudy, B.; Moore, J. P.; Sakmar, T. P.; Dragic, T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 2003, 77, 5201-5208.
31. Tagat, J. R.; Steensma, R. W.; McCombie, S. W.; Nazareno, D. V.; Lin, S. I.; Neustadt, B. R.; Cox, K.; Xu, S.; Wojcik, L.; Murray, M. G.; Vantuno, N.; Baroudy, B. M.; Strizki, J. M. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S) -[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist J. Med. Chem. 2001, 44, 3343-3346.
32. Tagat, J. R.; McCombie, S. W.; Steensma, R. W.; Lin, S.; Nazareno, D. V. ; Baroudy, B.; Vantuno, N.; Xu, S.; Liu, J. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-Methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 2001, 11, 2143-2146.
33. McCombie, S. W.; Tagat, J. R.; Vice, S. F.; Lin, S. I.; Steensma, R.; Palani, A.; Neustadt, B. R.; Baroudy, B. M.; Strizki, J. M.; Endres, M. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003, 13, 567-571.
34. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
35. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
36. Güner, O. F. Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, CA, 1999.
37. Barreca, M. L.; Gitto, R.; Quartarone, S.; De Luca, L.; De Sarro, G.; Chimirri, A. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. J. Chem. Inf. Comput. Sci. 2003, 43, 651-655.
38. Beno, B. R.; Mason, J. S. The design of combinatorial libraries using properties and 3D pharmacophore fingerprints. Drug Discovery Today 2001, 6, 251-258.
39. Bostrom, J.; Gundertofte, K.; Liljeforsa, T. A pharmacophore model for dopamine D4 receptor antagonists. J. Comput.-Aided Mol. Des. 2000, 14, 769-786.
40. Bremner, J. B.; Coban, B.; Griffith, R. Pharmacophore development for antagonists at alpha 1 adrenergic receptor subtypes. J. Comput.-Aided Mol. Des. 1996, 10, 545-557.
41. Carlson, H. A.; Masukawa, K. M.; Rubins, K.; Bushman, F. D.; Jorgensen, W. L.; Lins, R. D.; Briggs, J. M.; McCammon, J. A. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 2000, 43, 2100-2114.
42. Chen, X.; Rusinko, A., III; Tropsha, A.; Young, S. S. Automated pharmacophore identification for large chemical data sets. J. Chem. Inf. Comput. Sci. 1999, 39, 887-896.
43. Debnath, A. K. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J. Med. Chem. 2002, 45, 41-53.
44. Ekins, S.; de Groot, M. J.; Jones, J. P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 2001, 29, 936-944.
45. Ekins, S.; Stresser, D. M.; Andrew Williams, J. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 2003, 24, 161-166.
46. Enyedy, I. J.; Sakamuri, S.; Zaman, W. A.; Johnson, K. M.; Wang, S. Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 513-517.
47. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K. H.; Zaharevitz, D. ; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K. C.; Fojo, T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2904-2909.
48. Guner, O. F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top. Med. Chem. 2002, 2, 1321-1332.
49. Hirashima, A.; Eiraku, T.; Shigeta, Y.; Kuwano, E. Three-dimensional pharmacophore hypotheses of octopamine/tyramine agonists which inhibit [1-14C]acetate incorporation in Plodia interpunctella. Bioorg. Med. Chem. 2003, 11, 95-103.
50. Joseph-McCarthy, D.; Thomas, B. E.; Belmarsh, M.; Moustakas, D.; Alvarez, J. C. Pharmacophore-based molecular docking to account for ligand flexibility. Proteins 2003, 51, 172-188.
51. Koide, Y.; Tatsui, A.; Hasegawa, T.; Murakami, A.; Satoh, S.; Yamada, H. ; Kazayama, S.; Takahashi, A. Identification of a stable chymase inhibitor using a pharmacophore-based database search. Bioorg. Med. Chem. Lett. 2003, 13, 25-29.
52. Krovat, E. M.; Langer, T. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J. Med. Chem. 2003, 46, 716-726.
53. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
54. Malawska, B.; Scatturin, A. Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini-Rev. Med. Chem. 2003, 3, 341-348.
55. Marriott, D. P.; Dougall, I. G.; Meghani, P.; Liu, Y. J.; Flower, D. R. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists. J. Med. Chem. 1999, 42, 3210-3216.
56. Patel, Y.; Gillet, V. J.; Bravi, G.; Leach, A. R. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comput.-Aided Mol. Des. 2002, 16, 653-681.
57. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22, 151-185.
58. McCombie, S. W.; Tagat, J. R.; Vice, S. F.; Lin, S. I.; Steensma, R.; Palani, A.; Neustadt, B. R.; Baroudy, B. M.; Strizki, J. M.; Endres, M.; Cox, K.; Dan, N.; Chou, C. C. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003, 13, 567-571.
59. Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Vice, S.; McCombie, S.; Cox, K.; Strizki, J.; Baroudy, B. M. Oximinopiperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003, 13, 709-712.
60. Li, H.; Sutter, J.; Hoffman, R. HypoGen: An automated system for generating 3D predictive pharmacophore models. In Pharmacophore Perception, Development, and Use in Drug Design; Guner, O. F., Ed.; International University Line: La Jolla, CA, 1999; pp 173-189.
61. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
62. Smellie, A. Poling: Promoting Conformational Variation. J. Comput. Chem. 1995, 16, 171-187.
63. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
64. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Space. 2. Application of Conformational Models J. Chem. Inf. Comput. Sci. 1995, 16, 295-304.
65. Sutter, J.; Güner, O. F.; Hoffman, R.; Li, H.; Waldman, M. Effect of Variable Weight and Tolerances on Predictive Model Generation. In Pharmacophore Perception, Development, and Use in Drug Design; Guner, O. F., Ed.; International University Line: La Jolla, CA, 1999; pp 501-511.
66. Hirashima, A.; Shigeta, Y.; Eiraku, T.; Kuwano, E. Inhibitors of Calling Behavior of Plodia interpunctella. J. Insect Sci. 2003, 3, 4.
67. Bremner, J. B.; Castle, K.; Griffith, R.; Keller, P. A.; Ridley, D. D. Mining the Chemical Abstracts database with pharmacophore-based queries. J. Mol. Graphics Modell. 2002, 21, 185-194.
68. Clark, D. E.; Westhead, D. R.; Sykes, R. A.; Murray, C. W. Active-site-directed 3D database searching: pharmacophore extraction and validation of hits. J. Comput.-Aided Mol. Des. 1996, 10, 397-416.
69. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W.; Pommier, Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
70. Sprague, P. W. Automated chemical hypothesis generation and database searching with Catalyst. In Perspectives in Drug Discovery and Design; Müller, K., Ed.; ESCOM Science Publishers B.V.: Leiden, The Netherlands, 1995; pp 1-21.
71. Hale, J. J.; Budhu, R. J.; Holson, E. B.; Finke, P. E.; Oates, B.; Mills, S. G.; MacCoss, M.; Gould, S. L.; DeMartino, J. A.; Springer, M. S.; Siciliano, S.; Malkowitz, L.; Schleif, W. A.; Hazuda, D.; Miller, M.; Kessler, J.; Danzeisen, R.; Holmes, K.; Lineberger, J.; Carella, A.; Carver, G.; Emini, E. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. Bioorg. Med. Chem. Lett. 2001, 11, 2741-2745.
72. Hale, J. J.; Budhu, R. J.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Siciliano, S.; Gould, S. L.; DeMartino, J. A.; Springer, M. S. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg. Med. Chem. Lett. 2001, 11, 1437-1440.
73. Hale, J. J.; Budhu, R. J.; Mills, S. G.; MacCoss, M.; Gould, S. L.; DeMartino, J. A.; Springer, M. S.; Siciliano, S. J.; Malkowitz, L.; Schleif, W. A. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity. Bioorg. Med. Chem. Lett. 2002, 12, 2997-3000.
74. Lynch, C. L.; Hale, J. J.; Budhu, R. J.; Gentry, A. L.; Mills, S. G.; Chapman, K. T.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Gould, S. L. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. Bioorg. Med. Chem. Lett. 2002, 12, 3001-3004.
75. Lynch, C. L.; Willoughby, C. A.; Hale, J. J.; Holson, E. J.; Budhu, R. J.; Gentry, A. L.; Rosauer, K. G.; Caldwell, C. G.; Chen, P.; Mills, S. G. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains. Bioorg. Med. Chem. Lett. 2003, 13, 119-123.
76. Lynch, C. L.; Gentry, A. L.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Gould, S. L.; DeMartino, J. A.; Siciliano, S. J. CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. Bioorg. Med. Chem. Lett. 2002, 12, 677-679.
77. Castonguay, L. A.; Weng, Y.; Adolfsen, W.; Di Salvo, J.; Kilburn, R.; Caldwell, C. G.; Daugherty, B. L.; Finke, P. E.; Hale, J. J.; Lynch, C. L.; Mills, S. G.; MacCoss, M.; Springer, M. S.; DeMartino, J. A. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 2003, 42, 1544-1550.
78. Dorn, C. P.; Finke, P. E.; Oates, B.; Budhu, R. J.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.; Gould, S. L.; DeMartino, J. A.; Siciliano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11, 259-264.
79. Finke, P. E.; Oates, B.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Gould, S. L.; DeMartino, J. A.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl) -N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11, 2475-2479.
80. Finke, P. E.; Meurer, L. C.; Oates, B.; Shah, S. K.; Loebach, J. L.; Mills, S. G.; MacCoss, M.; Castonguay, L.; Malkowitz, L.; Springer, M. S.; Gould, S. L.; DeMartino, J. A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted) piperidin-1-yl]butanes. Bioorg. Med. Chem. Lett. 2001, 11, 2469-2473.
81. Finke, P. E.; Meurer, L. C.; Oates, B.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.; Gould, S. L.; DeMartino, J. A.; Siciliano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11, 265-270.
82. Kim, D.; Wang, L.; Caldwell, C. G.; Chen, P.; Finke, P. E.; Oates, B.; MacCoss, M.; Mills, S. G.; Malkowitz, L.; Gould, S. L.; DeMartino, J. A.; Springer, M. S.; Hazuda, D.; Miller, M.; Kessler, J.; Danzeisen, R.; Carver, G. ; Carella, A.; Holmes, K.; Lineberger, J.; Schleif, W. A.; Emini, E. A. Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Bioorg. Med. Chem. Lett. 2001, 11, 3103-3106.
83. Kim, D.; Wang, L.; Caldwell, C. G.; Chen, P.; Finke, P. E.; Oates, B.; MacCoss, M.; Mills, S. G.; Malkowitz, L.; Gould, S. L.; DeMartino, J. A.; Springer, M. S.; Hazuda, D.; Miller, M.; Kessler, J.; Danzeisen, R.; Carver, G. ; Carella, A.; Holmes, K.; Lineberger, J.; Schleif, W. A.; Emini, E. A. Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. Bioorg. Med. Chem. Lett. 2001, 11, 3099-3102.
84. Armour, D. R.; Price, D. A.; Stammen, B. L. C.; Wood, A.; Perros, M.; Edwards, M. P. Piperidines as CCR5 Modulators. Patent WO 00/39125, 2000.
85. Armour, D. R.; Price, D. A.; Stammen, B. L. C.; Wood, A.; Perros, M.; Edwards, M. P. Aminoazacycloalkanase as CCR5 modulators. Patent EP-1013276, 2000.
86. Bondinell, W. E. Propenamides as CCR5 Modulators. Patent WO 00/06153, 2000.
87. Ku, T. W.; Bondinell, W. E.; Neeb, M. J. Substituted Anilide Compounds and Methods. Patent WO 00/06146, 2000.